Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute  by Nomori, Hiroaki et al.
Nomori et al General Thoracic SurgerySegmentectomy for selected cT1N0M0 non–small cell lung cancer:
A prospective study at a single instituteHiroaki Nomori, PhD,a Takeshi Mori, PhD,b Koei Ikeda, PhD,b Kentaro Yoshimoto, PhD,b
Kenichi Iyama, PhD,c and Makoto Suzuki, PhDbFrom th
cine,
moto
Disclos
Receive
publi
Address
gery,
chi, S
0022-52
Copyrig
doi:10.1
G
T
SBackground: To examine whether segmentectomy is radical for cT1N0M0 non–small cell lung cancer
(NSCLC), a prospective single-arm study was performed at a single institution.
Methods: The criteria for segmentectomy were as follows: (1) peripheral-type cT1N0M0 NSCLC; (2) intrao-
perative frozen sections of sentinel nodes identified with isotope showing no metastasis; (3) surgical margins
greater than 2 cm; (4) patient choice for segmentectomy; and (5) exclusion of right middle lobe tumors.
From 2005 to 2009, of 245 patients with cT1N0M0 NSCLC, 195 (80%) were enrolled in the present study.
Of these 195 patients, 179 ultimately underwent segmentectomy with systematic lymph node dissection. Of
these 179 patients, 134 (75%) had tumors 2 cm or smaller, and 45 (25%) had tumors 2.1 cm to 3 cm. The median
follow-up period was 43 months.
Results: All 181 tumors from 179 patients were stage pN0. Of the 179 patients, 6 developed distant site recur-
rence and 3 local recurrence (ie, 1 developed pulmonary metastases within the same lobe 21 months after seg-
mentectomy and 2 developed local recurrence at the surgical margin 60 and 62 months after segmentectomy,
respectively). The 5-year overall survival was 94% for patients with tumors 2 cm or smaller and 81% for those
with 2.1-cm to 3-cm tumors. Postoperative pulmonary function was preserved at 90%  12% of preoperative
levels.
Conclusions: Segmentectomy with systematic lymph node dissection with a sufficient surgical margin could
be a radical treatment for selected cT1N0M0/pN0 NSCLC while preserving pulmonary function. The
surgical margin should be monitored for the development of local recurrence for a long period after segmentec-
tomy. (J Thorac Cardiovasc Surg 2012;144:87-93)Earn CME credits at
http://cme.ctsnetjournals.org
Recent advances in radical and anatomic pulmonary seg-
mentectomy are going to change the surgical procedures
for clinical T1N0M0 non–small cell lung cancer
(NSCLC).1 Although the Lung Cancer Study Group, from
the results of a prospective randomized controlled trial of
sublobar resection vs lobectomy for clinical stage
T1N0M0 NSCLC, concluded that the former was inferior
to the latter owing to greater local recurrence and poorer
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The Journal of Thoracic and Ca similar prognosis between lobectomy and segmentectomy
in patients with cT1N0M0 NSCLCs.3-5 However, the
radicality of segmentectomy remains controversial owing
to the variability of patient selection by each surgeon.
On the basis of our hypothesis that radical segmentec-
tomy could play a role in local control for T1N0M0
NSCLC, as well as does lobectomy, provided that sufficient
lymph node dissection was conducted, we began a prospec-
tive study of segmentectomy with our own criteria for pa-
tients with cT1N0M0 NSCLC at Kumamoto University
Hospital in 2005.6 For radical segmentectomy, we dissected
the hilar mediastinal lymph nodes to the extent possible and
examined them to identify the sentinel node (SN) using ra-
dioisotopes.7,8 When the intraoperative frozen SN sections
indicated metastasis or the surgical margin was insufficient,
we usually conducted completion lobectomy. Therefore, the
radical segmentectomy described in the present study
should be distinguished from simple segmentectomy by
the extent of lymph node dissection. It seems similar to
the ‘‘radical lobectomy’’ proposed by Cahan9 in 1960,
when pneumonectomy was the standard procedure. Cahan9
defined radical lobectomy as an operation in which 1 or 2
lobes were excised in a block dissection with their regional
hilar and mediastinal lymph nodes. After his proposal, lo-
bectomy with mediastinal lymph node dissection replacedardiovascular Surgery c Volume 144, Number 1 87
FIGURE 1. Treatment flow chart. NSCLC, Non–small cell lung cancer.
TABLE 1. Patient characteristics for planning segmentectomy
Characteristic Value
Age (y)
Mean 66  10
Range 29–83
Gender
Male 97
Female 98
Preoperative pulmonary function
FEV1/FVC (%)
Mean 73  10
Range 38–94
%FEV1
Mean 109  21
Range 49–180
FEV1, Forced expiratory volume in 1 second; FVC, forced vital capacity.
Abbreviations and Acronyms
DFS ¼ disease-free survival
FEV1 ¼ forced expiratory volume in 1 second
NSCLC ¼ non–small cell lung cancer
OS ¼ overall survival
SN ¼ sentinel node
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Spneumonectomy, even for stage N1 or N2 disease, and this
technique has been established as the standard procedure
for NSCLC to date.
In the present study, to prove our hypothesis, we exam-
ined the long-term prognosis, recurrence pattern, and pul-
monary function after radical segmentectomy in patients
with cT1N0M0/pN0 NSCLC.
METHODS
Eligibility
The ethics committees of Kumamoto University approved the study
protocol for segmentectomy using radioisotopes for SN identification in
patients with cT1N0M0 NSCLC. Clinical staging was performed by
body computed tomography scanning, brain magnetic resonance imaging,
and fluorodeoxyglucose-positron emission tomography. Lymph node bi-
opsy using endobronchial ultrasonography was conducted for swelling
lymph nodes, and mediastinoscopy was not undertaken. All patients pro-
vided informed consent after fully discussing the risks and benefits with
their surgeons. The inclusion criteria of segmentectomy were as follows:
(1) cT1N0M0 peripheral-type NSCLC; (2) a single lesion in 1 lobe; (3) in-
traoperative pleural lavage cytology showing no malignancy; (4) SN intra-
operative frozen section showing no metastasis; and (5) patient choice for
segmentectomy instead of lobectomy after informed consent. The exclu-
sion criteria were tumors within the right middle lobe and patients unable
to tolerate segmentectomy.
Patients
From April 2005 to March 2009, 245 patients with clinical stage
T1N0M0 NSCLC were referred to the Department of Thoracic Surgery
of Kumamoto University Hospital for surgical treatment (Figure 1). Of
these, segmentectomy was planned for 195 patients (80%) according to
the criteria described, 30 patients (12%) underwent lobectomy, and 20
(8%) underwent wedge resection. The reasons for conducting lobectomy
in the 30 patients were determined by our criteria as follows: (1) right mid-
dle lobe tumors in 15 patients; (2) multiple lesions in the same lobe in 7; (3)
centrally located tumors in 5; and (4) patient request for lobectomy in 3.
The reasons for conducting wedge resection in 20 patients were intolerance
to segmentectomy in 19 (forced expiratory volume in 1 second [FEV1]
<50% in 8 patients, severe comorbidities in 8, and old age in 3) and patient
request for wedge resection by the remaining patient. Of the 195 patients
scheduled for segmentectomy, 148 (76%) underwent SN identification us-
ing technetium-99m tin colloid or technetium-99m phytate, and 47 patients
did not (pure ground-glass opacity findings on computed tomography in 41
patients and old age in 6).
SN Identification
SNs were identified to target the nodes submitted for intraoperative fro-
zen section analysis but not to reduce the extent of lymph node dissection.
Administration of radiotracers was done using a previously reported
method.10-14 The identified SNs were used for intraoperative frozen88 The Journal of Thoracic and Cardiovascular Surgesection analysis with hematoxylin and eosin staining. The lymph node
nomenclature and tumor stage were according to the Staging Manual in
Thoracic Oncology by the International Association for the Study of
Lung Cancer in 2009.15
Nomenclature of Segments
The nomenclature of pulmonary segments was defined as follows: the
apical, dorsal, and ventral segment of the right upper lobe was S1, S2,
and S3, respectively; the apicodorsal, ventral, lingular superior, and lingu-
lar inferior of the left upper lobe was S1þS2, S3, S4, and S5, respectively;
the superior, mediobasal, ventrobasal, lateral basal, and dorsobasal of the
lower lobe was S6, S7, S8, S9, and S10, respectively.ry c July 2012
TABLE 2. Patients with metastasis in sentinel nodes diagnosed by intraoperative frozen section analysis
Pt. no. Age (y)/gender Histologic type Planned segmentectomy SN with metastasis Procedure pTNM stage
1 72/M Adenocarcinoma Right S6 11 Lobectomy T1aN1M0
2 54/F Adenocarcinoma Left S9þS10 12 Lobectomy T2aN2M0
3 50/F Adenocarcinoma Left S1þS2þS3 5, 10 Lobectomy T1bN2M0
4 69F Adenocarcinoma Left S1S3 5 Lobectomy T2aN2M0
5 73/M SCC Left S1þ2 5 Lobectomy T1aN2M0
6 80/M Adenocarcinoma Left S1þS2 5 Left S1þS2þS3 T1bN2M0
7 81/M Adenocarcinoma Left S4þS5 5 Left S4þS5 T1aN2M0
Pt. no., Patient number; SN, sentinel node; M, male; F, female; SCC, squamous cell carcinoma.
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Immediately after thoracotomy, the surface of the visceral pleura over
the tumor was irrigated with a jet stream of saline solution using a 20-mL
syringe and the fluid collected for cytologic analysis. Under thoracotomy,
segmentectomy with systematic lymph node dissection was performed as
reported previously.6-8 The hilar nodal stations were completely dissected
with taping of segmental vessels and bronchi. After lymph node
dissection, the SNs were examined by intraoperative frozen section
analysis. The sections were serially cut at about 3 mm thickness. If the
SN could not be identified because of low radioactivity in the nodes,
the number 10 to 13 nodes and lobe-specific mediastinal nodes were sub-
mitted for frozen section analysis. When frozen section analysis of SN
demonstrated metastasis, completion lobectomy was performed. During
surgery, the surgical margin was confirmed to be sufficiently greater
than 2 cm or the maximum diameter of the tumor. If the surgical margin
was insufficient on the cut surface of the specimens, completion lobec-
tomy was performed.
Pulmonary Function Test
The vital capacity, forced vital capacity, and FEV1 were measured in the
seated position using a dry rolling-seal spirometer (CHESTAC-9800DN;
Chest, Tokyo, Japan) in accordance with the American Thoracic Society
standards.16 Preoperative pulmonary function was measured within 1
month before surgery, and postoperative function was measured at least
6 months after surgery (median, 6 months; range, 6–17 months). Pre-
and postoperative pulmonary function was measured in 169 (94%) of
the 179 patients.
Pathologic Diagnosis
Formalin-fixed surgical specimens were processed by routine hematox-
ylin and eosin staining and elastica van Gieson staining. The histologic sub-
types were classified according to the World Health Organization
classification.17
Postoperative Follow-up
All patients were followed up every 3 to 6 months after surgery until 5
years postoperatively and yearly thereafter. The follow-up period ranged
from 5 to 74 months, with an average and median period of 43 months.TABLE 3. Patients undergoing completion lobectomy because of insufficie
Pt. no. Age (y)/Gender Histologic type Tumor size (cm)
1 52/M Adenocarcinoma 1.3
2 60/M Adenocarcinoma 1.4
3 73/M Adenocarcinoma 1.7
4 53/M BAC 1.8
5 71/M SCC 2.0
6 68/F Adenocarcinoma 2.3
7 80/M BAC 2.5
Pt. no., Patient number; M, male; BAC, bronchioloalveolar carcinoma; SCC, squamous ce
The Journal of Thoracic and CStatistical Analysis
A chi-square test or t-test was used for intergroup comparisons. Survival
was estimated using the Kaplan-Meier method,18 and differences in sur-
vival between the tumor groups were determined using log-rank analysis.
The survival period from the date of segmentectomy to the date of the
last follow-up examination or death was used for the estimation.
Disease-free survival (DFS) was the interval from segmentectomy to
proven detection of recurrence, death, or the last follow-up visit. Death
caused by other disease was included as an event in the analysis of DFS.
Univariate and multivariate Cox proportional hazards regression models
were used to compare the groups and generate the hazard ratios and
95% confidence intervals. Multivariate models were adjusted for age, gen-
der, tumor size, histologic type, and pleural invasion. Values of P< .05
were accepted as indicating statistical significance.
RESULTS
The characteristics of the 195 patients who were sched-
uled for segmentectomy are listed in Table 1. Of these pa-
tients, 3 had a%FEV1 less than 60%.
Of the 195 patients scheduled for segmentectomy, 7 were
diagnosed with lymph node metastasis according to the
findings from intraoperative frozen section analysis of the
SN (Table 2). Of these 7 patients, 5 underwent completion
lobectomy, and 2 underwent segmentectomy because of
their old age (patients 6 and 7). Another 7 patients with
an insufficient surgical margin with segmentectomy under-
went completion lobectomy (Table 3). One patient demon-
strated positive pleural lavage cytology and therefore
underwent lobectomy. Another patient underwent comple-
tion exploratory thoracotomy, owing to tumor pleural dis-
semination. Thus, 179 patients were ultimately treated by
segmentectomy alone (Figure 1). Two patients had double
cT1N0M0 NSCLCs located in different lobes that were
treated by segmentectomy of each lobe, resulting in a total
of 181 tumors.nt surgical margins
Planned segmentectomy Converted procedure pTNM stage
Left S1þS2 Lobectomy T1aN0M0
Right S1þS2 Lobectomy T1aN0M0
Left S6 Lobectomy T1aN0M0
Right S6 Lobectomy T1aN0M0
Left S6bþS8aþS9a Lobectomy T1aN0M0
Right S3 Lobectomy T1bN0M0
Right S3þS2b Lobectomy T1bN0M0
ll carcinoma; F, female.
ardiovascular Surgery c Volume 144, Number 1 89
TABLE 4. Characteristics of tumors treated by segmentectomy
Characteristic
Tumor size (cm)
Total2 2.1–3
Mean tumor size (cm) 1.4  0.4 2.5  0.3 1.7  0.6
Tumor location
Right upper lobe 43 14 57
Right lower lobe 35 9 44
Left upper lobe 40 17 57
Left lower lobe 16 5 21
Right upper and lower lobes 1 0 1
Right upper and left lower lobes 1 0 1
Resected segments (n)
Mean 1.6  0.6 1.5  0.6 1.5  0.6
Range 1–4 1–4 1–4
Histologic type
Adenocarcinoma 51 25 76
Bronchioloalveolar carcinoma 77* 8 85
Squamous cell carcinoma 6 10 16
Adenosquamous carcinoma 2 2 4
Pathologic stage
T1N0M0 131 39 170
T2N0M0 5 6 11
Total (n) 136 45 181
*Significant difference between the 2 groups (P<.001).
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timately treated by segmentectomy are listed in Table 4. Of
the 181 tumors, 136 (75%) were 2 cm or less in size and 45
(25%) were 2.1 cm to 3 cm. The distribution of tumor-
containing lobes and the number of resected segments did
not differ between those 2 cm or less and those 2.1 cm to
3 cm. The histologic type was adenocarcinoma in 76,
bronchioloalveolar carcinoma (BAC) in 85, squamous cell
carcinoma in 16, and adenosquamous carcinoma in 4. Of
the 136 tumors 2 cm or less, 77 (57%) were BAC, a signif-
icantly greater rate than the 8 BACs (18%) in the 45 tumors
2.1 cm–3 cm in size (P<.001). Of the 136 tumors 2 cm or
less, 6 (4%) were squamous cell carcinoma, a significantly
lower rate than the 10 squamous cell carcinoma (22%) of
the 45 tumors 2.1 cm to 3 cm in size (P< .001). TheTABLE 5. Characteristics of patients who developed recurrence after segm
Pt. no. Age/gender Histologic type Size (cm) pTNM stage
1 79/M SCC 1.8 T1aN0M0
2 63/M SCC 2.5 T1bN0M0
3 78/M SCC 2.5 T1bN0M0
4 70/F SCC 2.2 T1bN0M0
5 77/F Adenocarcinoma 1.4 T1aN0M0
6 80/F SCC 2.5 T1bN0M0
7 70/F Adenocarcinoma 2.0 T1aN0M0
8 76/M Adenocarcinoma 2.0 T1aN0M0
9 65/M Adenocarcinoma 2.4 T1bN0M0
Pt. no., Patient number; M, male; SCC, squamous cell carcinoma; LN, lymph node; F, fem
ySame lobe.
90 The Journal of Thoracic and Cardiovascular Surgepathologic tumor stage was T1N0M0 in 170 tumors and
T2N0M0 because of visceral pleural invasion (p1–p3)
in 11.
No operative mortality occurred in 179 patients. The
chest tube was removed within a mean of 2.1  2.8 days
(median, 2 days; range, 1–29 days) after segmentectomy.
Three patients developed prolonged postoperative air leak-
age of more than 7 days. Postoperative pneumonia occurred
in 1 patient with diabetes mellitus and low FEV1/forced vi-
tal capacity (48%), who was discharged from the hospital
after recovery. No other major morbidity was observed.
The 9 patients had recurrence after segmentectomy
(Table 5). Six patients (patients 1–6) presented with their
first recurrence at distant sites and 3 (patients 7–9) at local
sites. The site of local recurrence in the 3 patients was pul-
monary metastases (2 lesions) within the same lobe in 1
patient (patient 7) and the surgical margin in 2 (patients
8 and 9). The pulmonary metastases within the same
lobe in the former patient occurred 21 months after seg-
mentectomy. The local recurrence at the surgical margin
in the latter 2 patients occurred 60 and 62 months after
segmentectomy, respectively; the histologic type of the
primary tumor was adenocarcinoma with a BAC pattern.
These 3 patients with local recurrence also underwent
completion lobectomy, resulting in subsequent disease-
free recovery. Five patients died with other diseases.
Thus, 165 patients have been healthy without disease since
segmentectomy.
Figure 2 shows the overall survival (OS) and DFS. The
5-year OS and DFS of all 179 patients was 91% and
91%, respectively (Figure 2, A and B). The 5-year OS of
the BAC (n ¼ 84) and non-BAC cases (n ¼ 95) was 97%
and 86%, respectively, a significant difference (P ¼ .04;
Figure 2, C). The 5-year DFS of BAC and non-BAC cases
(97% and 85%, respectively) was also significantly differ-
ent (P¼ .006; Figure 2,D). The 5-year OS of tumors 2.0 cm
or less and 2.1 cm to 3.0 cm in size was 94% and 81%, re-
spectively, a significant difference (P ¼ .006; Figure 2, E).
The 5-year DFS of tumors 2.0 cm or less and 2.1 cm to 3.0
cm in size (95% and 79%, respectively) also differedentectomy
Procedure Recurrence site (time) Prognosis (time)
Right S6 LN* (9 m) Dead (13 m)
Right S1 Pleura (7 m) Dead (22 m)
Left S1þS2 Liver (15 m) Dead (27 m)
Right S6 Bilateral lung (40 m) Dead (43 m)
Right S3 Bilateral lung (10 m) Alive (57 m)
Left S1þS2 SCNþbilateral lung (10 m) Alive (53 m)
Right S1þS2 Lungy (21 m) Alive (42 m)
Left S3 Surgical margin (60 m) Alive (64 m)
Right S3þS2b Surgical margin (62 m) Alive (64 m)
ale; SCN, supraclavicular lymph node. *Bilateral mediastinal and hilar lymph nodes.
ry c July 2012
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FIGURE 2. A,Overall survival (OS) for all total patients. B, Disease-free survival (DFS) for all patients. C, OS for thosewith bronchioloalveolar carcinoma
(BAC) and non-BAC. D, DFS for thosewith BAC carcinoma and non-BAC. E, OS for thosewith tumors 2 cm or less and 2.1 cm to 3 cm. F, DFS for thosewith
tumors 2 cm or less and 2.1 cm to 3 cm.
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male and female patients (86% and 95%, respectively)
also differed significantly (P ¼ .04). The 5-year DFS of pa-
tients with stage p0 tumors and p1–p3 tumors (93% and
63%, respectively) also differed significantly (P ¼ .04).
No significant difference was found in the 5-year DFS be-
tween patients with 65 years old or younger and older
than 65 years (96% and 86%, respectively, P ¼ .11).The Journal of Thoracic and CThe results of the multivariate analysis of DFS for
gender, age, tumor size, histologic type, and pleural inva-
sion are listed in Table 6; none reached statistical
significance.
The mean postoperative FEV1/preoperative FEV1 was
90%  12% (Figure 3). Regarding the number of resected
segments, 96 patients were treated by resection of 1 seg-
ment, 65 patients by 1.5 or 2 segments, and 10 patients byardiovascular Surgery c Volume 144, Number 1 91
TABLE 6. Multivariate analysis of disease-free survival for gender,
age, tumor size, histologic type, and pleural invasion
Variable Hazard ratio P value
Gender (male vs female) 2.26 .16
Age (>65 vs 65 y) 2.48 .10
Tumor size (2–3 vs 2 cm) 2.64 .08
Histologic type (non-BAC vs BAC) 3.71 .07
Pleural invasion (p1–p3 vs p0) 1.24 .75
BAC, Bronchioloalveolar carcinoma.
Post/Pre FEV1(%)
0
70
80
90
100
All cases
Number of resected segments
1(n=96) 1.5-2(n=65) 2.5- (n=10)
NS
Preservation of pulmonary function
FIGURE 3. Preservation of pulmonary function. FEV1, Forced expiratory
volume in 1 second; NS, not significant.
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Smore than 2.5 segments. The corresponding postoperative
FEV1/preoperative FEV1 values of these patient groups
were 90%  10%, 89%  13%, and 87%  10%, with
no significant differences among the 3 groups.
DISCUSSION
The results of the present study highlight the following
points. First, the prognosis after segmentectomy was not in-
ferior to that generally reported after lobectomy. Second,
SN identification was useful for intraoperative N staging.
Third, although 3 patients developed local recurrences,
none developed recurrence at the regional lymph nodes.
Fourth, postoperative pulmonary function was preserved
at approximately 90% of the preoperative levels. Finally,
preservation of postoperative pulmonary function did not
differ according to the number of resected segments.
In the present study, the 5-year OS after segmentectomy
was 91%, similar to that previously reported after lobec-
tomy in patients with stage IA NSCLC.3-5,19 One of the
most remarkable findings of the present study was that
local recurrence developed in only 3 patients (1.7%) and
none of the patients developed recurrence in the regional
lymph nodes, which could be the result of our extended
lymph node dissection and intraoperative N-staging using
SN identification.
In the present study, SNs were identified using radioiso-
topes for intraoperative N-staging. However, we do not con-
sider SN identification to be always necessary during
segmentectomy. If SN identification is not used during seg-
mentectomy, in principle, all the dissected lymph nodes
should be submitted for frozen section analysis in its place,
because the frequency of lymph node metastasis in
cT1N0M0 NSCLC has been reported be approximately
10% according to the Japanese Lung Cancer Registry
from 2004.19 However, intraoperative frozen examination
of all dissected lymph nodes is not usually available. There-
fore, when not using SN identification, we recommend the
following methods to target lymph nodes submitted for fro-
zen section analysis during segmentectomy. First, in the hilar
lymph nodes, nodes 12 and 13, at least, should be submitted
for frozen section analysis, rather than node 10 or 11, be-
cause our previous study indicated that the rate of nodes
12 and 13 being a SN was 39% and 57%, respectively,
and that of nodes 10 and 11 was only 10% and 16%,92 The Journal of Thoracic and Cardiovascular Surgerespectively.11 Second, in the mediastinal nodes, the lobe-
specific nodes should be submitted for frozen section
analysis.
In the 2 patients who developed local recurrence at the
surgical margin, the primary tumors of both patients were
histologically typed as adenocarcinoma demonstrating
a BAC pattern at the periphery. These recurrences devel-
oped more than 5 years after segmentectomy. Although
the surgical margins on the resected specimens at seg-
mentectomy in both patients had been confirmed as suffi-
cient on the formalin-fixed sections, their recurrence
might have been caused by BAC spreading at the other
margins, resulting in recurrence long after surgery. Seg-
mentectomy in these 2 patients was conducted within
the first year after the beginning of the study, which
might have still represented a learning curve for radical
segmentectomy. Since 2 years after beginning the study,
we have used a ring-shaped forceps 3 cm to 5 cm in di-
ameter to grasp the whole tumor, followed by cutting
lung tissue away from the forceps. We believe that this
technique is useful for taking a sufficient surgical margin
during segmentectomy.
Even with extensive lymph node dissection and sufficient
surgical margins during segmentectomy, pulmonary metas-
tasis within the same lobe can be missed. In the present
study, 1 patient developed pulmonary metastases within
the same lobe after segmentectomy. However, the recent de-
velopment of high-resolution computed tomography can
identify pulmonary lesions even 0.2 cm in size, which could
lead to the correct indication for segmentectomy.
Postoperative pulmonary function after segmentectomy
was preserved at approximately 90% of the preoperative
values in the present study, similar to the data reported by
several investigators.20-22 We previously examined the
preservation of pulmonary function in each lobe treated
by segmentectomy using perfusion scanning with singlery c July 2012
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Sphoton emission computed tomography, which indicated
a significant decrease after resection of multiple segments
compared with resection of a single segment.23 However,
the present study, which measured overall pulmonary func-
tion using routine pulmonary function testing, showed no
significant difference according to the number of resected
segments.
To date, several investigators have reported the outcomes
of sublobar resection for cT1N0M0 2 cm or less in size.3-5
For cT1N0M0 NSCLC tumors 2.1 cm to 3 cm in size, the
indication of segmentectomy has been controversial. In
comparing the outcomes between segmentectomy and
lobectomy for tumors 2.1 cm to 3 cm, Okumura and
colleagues24 reported the former to be inferior to the latter,
but Okada and colleagues25 found no difference between
the 2 procedures. The present study demonstrated the
5-year OS and DFS of tumors 2.1 cm to 3 cm to be 81%
and 79%, respectively, similar to the Japanese Lung Cancer
Registry data from 2004, in which most patients were
treated by lobectomy. We, therefore, believe that segmen-
tectomy could be indicated for pT1N0M0 NSCLC even
for tumors 2.1 cm to 3 cm in size, provided that extended
lymph node dissection is performed and a sufficient surgical
margin is taken.
Although the univariate analysis showed the significance
of DFS for gender, tumor size, histologic type, and pleural
invasion, multivariate analysis showed any significance for
none of these factors, which could be caused by few events
(n ¼ 16) in the present study. We believe that a massive
study in the future will show the significance of DFS for
these factors, all well-known significant prognostic factors
for NSCLC.
The most significant limitation of the present study was
that it was a nonrandomized controlled study. Therefore,
we must await the outcomes of ongoing randomized con-
trolled trials between lobectomy and sublobar resection
from the United States and Japan. However, from the pres-
ent study, we believe that radical segmentectomy could play
a role in the local control of T1N0M0 NSCLC, as well as
lobectomy, provided that a sufficient lymph node dissection
was conducted.
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